Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB.

Cancer. 2019 Oct 22. doi: 10.1002/cncr.32557. [Epub ahead of print]

PMID:
31639200
2.

Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.

Zhao F, Vesprini D, Liu RSC, Olkhov-Mitsel E, Klotz LH, Loblaw A, Liu SK, Bapat B.

Urol Oncol. 2019 May;37(5):297.e9-297.e17. doi: 10.1016/j.urolonc.2019.01.031. Epub 2019 Feb 16.

PMID:
30777394
3.

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R.

Ann Appl Stat. 2018 Sep;12(3):1773-1795. doi: 10.1214/17-AOAS1130. Epub 2018 Sep 11.

4.

A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes.

Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):61-66. doi: 10.1016/j.ijrobp.2018.12.054. Epub 2019 Jan 6.

PMID:
30625410
5.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

6.
7.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

8.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.

PMID:
29331546
9.

Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance.

Guy DE, Vandersluis A, Klotz LH, Fleshner N, Kiss A, Parker C, Venkateswaran V.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):187-195. doi: 10.1038/s41391-017-0010-0. Epub 2017 Dec 14.

PMID:
29242596
10.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.

J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15. Review.

PMID:
29203269
11.
12.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

13.

Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.

Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi: 10.1038/pcan.2017.8. Epub 2017 Mar 28.

14.

The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.

Mayer MJ, Klotz LH, Venkateswaran V.

J Urol. 2017 Apr;197(4):1068-1075. doi: 10.1016/j.juro.2016.10.069. Epub 2016 Oct 28.

PMID:
27984108
15.

The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts.

Vandersluis AD, Guy DE, Klotz LH, Fleshner NE, Kiss A, Parker C, Venkateswaran V.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):305-10. doi: 10.1038/pcan.2016.22. Epub 2016 Jun 28.

PMID:
27349497
16.

New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men.

Wallis CJ, Mahar A, Cheung P, Herschorn S, Klotz LH, Al-Matar A, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK.

Eur Urol. 2016 May;69(5):933-41. doi: 10.1016/j.eururo.2015.10.043. Epub 2015 Nov 11.

PMID:
26572707
17.

Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study.

Nam RK, Amemiya Y, Benatar T, Wallis CJ, Stojcic-Bendavid J, Bacopulos S, Sherman C, Sugar L, Naeim M, Yang W, Zhang A, Klotz LH, Narod SA, Seth A.

J Cancer. 2015 Sep 15;6(11):1160-71. doi: 10.7150/jca.13397. eCollection 2015.

18.

Metformin and prostate cancer stem cells: a novel therapeutic target.

Mayer MJ, Klotz LH, Venkateswaran V.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):303-9. doi: 10.1038/pcan.2015.35. Epub 2015 Jul 28. Review.

PMID:
26215782
19.

A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.

Sasaki H, Klotz LH, Sugar LM, Kiss A, Venkateswaran V.

Biochem Biophys Res Commun. 2015 Aug 28;464(3):848-54. doi: 10.1016/j.bbrc.2015.07.050. Epub 2015 Jul 13.

PMID:
26182875
20.

Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.

Venier NA, Yamamoto T, Sugar LM, Adomat H, Fleshner NE, Klotz LH, Venkateswaran V.

Prostate. 2015 Sep;75(12):1300-11. doi: 10.1002/pros.23013. Epub 2015 Jun 5.

PMID:
26047020
21.

The effects of serum from prostate cancer patients with elevated body mass index on prostate cancer cells in vitro.

Mora BC, Fleshner NE, Klotz LH, Venkateswaran V.

Lipid Insights. 2015 Apr 19;8:11-9. doi: 10.4137/LPI.S23135. eCollection 2015.

22.

Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis.

Wallis CJ, Herschorn S, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK.

Urology. 2015 Mar;85(3):621-7. doi: 10.1016/j.urology.2014.11.037.

PMID:
25733275
23.

Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer.

Wallis CJ, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK.

Br J Cancer. 2015 Mar 17;112(6):977-82. doi: 10.1038/bjc.2015.54.

24.

Practice patterns of post-radical prostatectomy incontinence surgery in Ontario.

Wallis CJ, Herschorn S, Liu Y, Carr LK, Kodama RT, Klotz LH, Saskin R, Nam RK.

Can Urol Assoc J. 2014 Sep;8(9-10):E670-4. doi: 10.5489/cuaj.1959.

25.

Capsaicin: a novel radio-sensitizing agent for prostate cancer.

Venier NA, Colquhoun AJ, Sasaki H, Kiss A, Sugar L, Adomat H, Fleshner NE, Klotz LH, Venkateswaran V.

Prostate. 2015 Feb;75(2):113-25. doi: 10.1002/pros.22896. Epub 2014 Oct 13.

PMID:
25307418
26.

Active surveillance for clinically localized prostate cancer--a systematic review.

Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P.

J Surg Oncol. 2014 Jun;109(8):830-5. doi: 10.1002/jso.23584. Epub 2014 Mar 7. Review.

PMID:
24610744
27.

Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.

Nam RK, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA.

Lancet Oncol. 2014 Feb;15(2):223-31. doi: 10.1016/S1470-2045(13)70606-5. Epub 2014 Jan 17.

PMID:
24440474
28.

Still unconvinced on the use of salvage prostatectomy.

Klotz LH.

Can Urol Assoc J. 2013 Mar-Apr;7(3-4):93. doi: 10.5489/cuaj.572. No abstract available.

29.

Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts.

Vandersluis AD, Venier NA, Colquhoun AJ, Sugar L, Pollak M, Kiss A, Fleshner NE, Klotz LH, Venkateswaran V.

Prostate. 2013 Aug;73(11):1223-32. doi: 10.1002/pros.22673. Epub 2013 Apr 30.

PMID:
23630020
30.

Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.

Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA.

J Urol. 2013 Jan;189(1 Suppl):S12-7; discussion S17-8. doi: 10.1016/j.juro.2012.11.015.

PMID:
23234616
31.
32.

Active surveillance for low-risk prostate cancer.

Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R.

Crit Rev Oncol Hematol. 2013 Mar;85(3):295-302. doi: 10.1016/j.critrevonc.2012.07.005. Epub 2012 Aug 9. Review.

PMID:
22878262
33.

Population based study of long-term rates of surgery for urinary incontinence after radical prostatectomy for prostate cancer.

Nam RK, Herschorn S, Loblaw DA, Liu Y, Klotz LH, Carr LK, Kodama RT, Stanimirovic A, Venkateswaran V, Saskin R, Law CH, Urbach DR, Narod SA.

J Urol. 2012 Aug;188(2):502-6. doi: 10.1016/j.juro.2012.04.005. Epub 2012 Jun 15.

PMID:
22704098
34.

Active surveillance for prostate cancer: a systematic review of the literature.

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS.

Eur Urol. 2012 Dec;62(6):976-83. doi: 10.1016/j.eururo.2012.05.072. Epub 2012 Jun 7. Review.

35.

Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.

Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V.

Prostate Cancer Prostatic Dis. 2012 Dec;15(4):346-52. doi: 10.1038/pcan.2012.16. Epub 2012 May 22.

PMID:
22614062
36.

Location, location, location: Prostate biopsies and MRIs.

Klotz LH.

Can Urol Assoc J. 2012 Apr;6(2):79, 81. doi: 10.5489/cuaj.12070. English, French. No abstract available.

37.

L'USPSTF et la FDA: l'APS et les I5AR.

Klotz LH.

Can Urol Assoc J. 2011 Dec;5(6):375-6. doi: 10.5489/cuaj.11275. No abstract available.

38.

USPSTF and FDA: PSA and 5ARIs.

Klotz LH.

Can Urol Assoc J. 2011 Dec;5(6):373-4. doi: 10.5489/cuaj.11274. No abstract available.

39.

New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort.

Nam RK, Zhang W, Siminovitch K, Shlien A, Kattan MW, Klotz LH, Trachtenberg J, Lu Y, Zhang J, Yu C, Toi A, Loblaw DA, Venkateswaran V, Stanimirovic A, Sugar L, Malkin D, Seth A, Narod SA.

Cancer Biol Ther. 2011 Dec 1;12(11):997-1004. doi: 10.4161/cbt.12.11.18366. Epub 2011 Dec 1.

40.

Le déclin et la chute des ECR.

Klotz LH.

Can Urol Assoc J. 2011 Aug;5(4):231. doi: 10.5489/cuaj.11149. No abstract available.

41.

The decline and fall of RCTs.

Klotz LH.

Can Urol Assoc J. 2011 Aug;5(4):229. doi: 10.5489/cuaj.11148. No abstract available.

42.

Statin Clinical Trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement.

Moyad MA, Klotz LH.

Urol Clin North Am. 2011 Aug;38(3):325-31. doi: 10.1016/j.ucl.2011.05.002.

PMID:
21798395
43.

Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.

Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, Klotz LH, Sugar L, Sherman C, Izawa J, Bell D, Stanimirovic A, Venkateswaran V, Diamandis EP, Yu C, Loblaw DA, Narod SA.

J Clin Oncol. 2011 Aug 1;29(22):2959-64. doi: 10.1200/JCO.2010.32.6371. Epub 2011 Jun 20.

PMID:
21690464
44.

JAUC met en œuvre les "sorties prématurées".

Klotz LH.

Can Urol Assoc J. 2011 Feb;5(1):9. doi: 10.5489/cuaj.11021. No abstract available.

45.

CUAJ implements early releases.

Klotz LH.

Can Urol Assoc J. 2011 Feb;5(1):7. doi: 10.5489/cuaj.11020. No abstract available.

46.

An unsung Canadian hero!

Klotz LH.

Can Urol Assoc J. 2010 Dec;4(6):371-2. English, French. No abstract available.

47.

Improving quality of care.

Klotz LH.

Can Urol Assoc J. 2010 Oct;4(5):299-301. English, French. No abstract available.

48.

Editorial comment.

Klotz LH.

Urology. 2010 Sep;76(3):700-1; discussion 701. doi: 10.1016/j.urology.2009.12.076. No abstract available.

PMID:
20832631
49.

Editorial comment.

Klotz LH.

Urology. 2010 Sep;76(3):692-3; discussion 693-4. doi: 10.1016/j.urology.2010.01.071. No abstract available.

PMID:
20832629
50.

Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Venkateswaran V, Klotz LH.

Nat Rev Urol. 2010 Aug;7(8):442-53. doi: 10.1038/nrurol.2010.102. Epub 2010 Jul 20. Review.

PMID:
20647991

Supplemental Content

Loading ...
Support Center